NCT04539808 2026-01-14NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic CancerOHSU Knight Cancer InstitutePhase 2 Active not recruiting42 enrolled 13 charts